Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Lenalidomide Enhancement of NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Is Mediated by Granzyme B and FasL and Is Associated with Modification of SHIP-1, PLC-g2 and pERK and Enhanced Chemokine Production.

Lei Wu, MD, Mary Adams, MS, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, Blake J. Bartlett, PhD

Blood (2007) 110 (11): 4885.

https://doi.org/10.1182/blood.V110.11.4885.4885

Published: 2007

Journal Articles

Lenalidomide Displays Direct Anti-Non-Hodgkin’s Lymphoma (NHL) Cell Activity in Association with Enhanced SPARC Expression but Independent of Its Ability to Strongly Inhibit NHL Cell VEGF Production In Vitro .

Ling-Hua Zhang, PhD, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, J. Blake Bartlett, PhD

Blood (2007) 110 (11): 3473.

https://doi.org/10.1182/blood.V110.11.3473.3473

Published: 2007

Journal Articles

Lenalidomide Strongly Enhances Natural Killer (NK) Cell Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) of Rituximab Treated Non-Hodkin’s Lymphoma Cell Lines In Vitro .

Lei Wu, MD, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, J. Blake Bartlett, PhD

Blood (2006) 108 (11): 3714.

https://doi.org/10.1182/blood.V108.11.3714.3714

Published: 2006

Journal Articles

Comparison of Anti-Angiogenic Activities of Thalidomide and Lenalidomide In Vitro.

Ling-Hua Zhang, PhD, Ling Lu, MS, Lei Wu, MS, Keith Dredge, PhD, J. Blake Bartlett, PhD, Peter Schafer, PhD, George Muller, PhD, Angus Dalgleish, PhD, David Stirling, PhD

Blood (2005) 106 (11): 3959.

https://doi.org/10.1182/blood.V106.11.3959.3959

Published: 2005

Journal Articles

Novel Immunomodulatory Drugs (IMiDs®): A Potential, New Therapy for β-Hemoglobinopathies.

Laure Moutouh de Parseval, MD., Helen Brady, PhD., Emila Glezer, MS., Normand Richard, MS., George Muller, PhD., Christopher L. Morris, MD., PhD., Dave Stirling, PhD., Kyle Chan, PhD.

Blood (2004) 104 (11): 3740.

https://doi.org/10.1182/blood.V104.11.3740.3740

Published: 2004

NARROW

Lenalidomide Enhancement of NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Is Mediated by Granzyme B and FasL and Is Associated with Modification of SHIP-1, PLC-g2 and pERK and Enhanced Chemokine Production.

Lenalidomide Displays Direct Anti-Non-Hodgkin’s Lymphoma (NHL) Cell Activity in Association with Enhanced SPARC Expression but Independent of Its Ability to Strongly Inhibit NHL Cell VEGF Production In Vitro .

Lenalidomide Strongly Enhances Natural Killer (NK) Cell Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) of Rituximab Treated Non-Hodkin’s Lymphoma Cell Lines In Vitro .

Comparison of Anti-Angiogenic Activities of Thalidomide and Lenalidomide In Vitro.

Novel Immunomodulatory Drugs (IMiDs®): A Potential, New Therapy for β-Hemoglobinopathies.

Email alerts

ASH Publications

American Society of Hematology

Lenalidomide Enhancement of NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Is Mediated by Granzyme B and FasL and Is Associated with Modification of SHIP-1, PLC-g2 and pERK and Enhanced Chemokine Production.

Lenalidomide Displays Direct Anti-Non-Hodgkin’s Lymphoma (NHL) Cell Activity in Association with Enhanced SPARC Expression but Independent of Its Ability to Strongly Inhibit NHL Cell VEGF Production In Vitro .

Lenalidomide Strongly Enhances Natural Killer (NK) Cell Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) of Rituximab Treated Non-Hodkin’s Lymphoma Cell Lines In Vitro .

Comparison of Anti-Angiogenic Activities of Thalidomide and Lenalidomide In Vitro.

Novel Immunomodulatory Drugs (IMiDs®): A Potential, New Therapy for β-Hemoglobinopathies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only